US pharmacy pricing
Where to Find the Cheapest Onzetra Xsail Price
Lowest price found · US pharmacies
$921.32/fill
for Onzetra Xsail, across the pharmacies in our data
US pharmacy prices — 2 exhaler powder
| Pharmacy | Discount-card price | Regular cash price | Average retail |
|---|---|---|---|
| $921.32Lowest | $924.32 | $73.34 | |
| $921.32Lowest | $924.32 | $73.34 | |
| $966.80 | $966.80 | $73.34 | |
| $968.19 | $971.19 | $73.34 | |
| $973.80 | $976.80 | $73.34 | |
| $975.08 | $978.08 | $73.34 | |
| $989.51 | $992.51 | $73.34 | |
| $989.51 | $992.51 | $73.34 | |
| $994.64 | $997.64 | $73.34 |
"Discount-card price" reflects a standard prescription discount card, not insurance. Prices change often — confirm at the pharmacy before filling.
Frequently asked questions
Is Onzetra Xsail (Onzetra Xsail) expensive if I don't have insurance?
At the US pharmacies in our data, the lowest listed discount-card price for Onzetra Xsail is around $921.32. Prices vary by pharmacy, dosage, and pack size, so use the table above to compare specific options near you.
Is a generic version of Onzetra Xsail available?
Generic and brand-name pricing for Onzetra Xsail is broken out in the tables above where both exist in our data. Generic versions are typically the lower-cost option, but availability depends on the specific formulation and dosage.
How much will Onzetra Xsail cost with my insurance plan?
Costs with insurance vary widely depending on your specific plan's formulary, copay, and deductible structure. It is essential to contact your insurer directly to confirm coverage details for this medication. For patients with Medicare or Medicaid, coverage is also plan-dependent. If your plan does not cover Onzetra Xsail or requires a high out-of-pocket cost, exploring pharmacy savings programs or manufacturer assistance may provide an alternative path to affordability.
Is a generic version of Onzetra Xsail available?
No. Onzetra Xsail is currently only available as a brand-name product from Currax Pharmaceuticals. A generic equivalent has not been approved for market.